These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

785 related items for PubMed ID: 25450955

  • 1. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
    Porrini V, Lanzillotta A, Branca C, Benarese M, Parrella E, Lorenzini L, Calzà L, Flaibani R, Spano PF, Imbimbo BP, Pizzi M.
    Neuroscience; 2015 Aug 27; 302():112-20. PubMed ID: 25450955
    [Abstract] [Full Text] [Related]

  • 2. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.
    Sivilia S, Lorenzini L, Giuliani A, Gusciglio M, Fernandez M, Baldassarro VA, Mangano C, Ferraro L, Pietrini V, Baroc MF, Viscomi AR, Ottonello S, Villetti G, Imbimbo BP, Calzà L, Giardino L.
    BMC Neurosci; 2013 Apr 05; 14():44. PubMed ID: 23560952
    [Abstract] [Full Text] [Related]

  • 3. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, Facchinetti F, Volta R, Pietrini V, Baroc MF, Serneels L, De Strooper B, Leon A.
    J Pharmacol Exp Ther; 2007 Dec 05; 323(3):822-30. PubMed ID: 17895400
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
    Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, Riccardi B, Puccini P, Moretto N, Grassi F, Ottonello S, Leon A.
    Pharmacol Res; 2007 Apr 05; 55(4):318-28. PubMed ID: 17292621
    [Abstract] [Full Text] [Related]

  • 5. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
    Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M.
    Br J Pharmacol; 2009 Mar 05; 156(6):982-93. PubMed ID: 19239474
    [Abstract] [Full Text] [Related]

  • 6. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
    Imbimbo BP, Giardino L, Sivilia S, Giuliani A, Gusciglio M, Pietrini V, Del Giudice E, D'Arrigo A, Leon A, Villetti G, Calzà L.
    J Alzheimers Dis; 2010 Mar 05; 20(1):159-73. PubMed ID: 20164581
    [Abstract] [Full Text] [Related]

  • 7. The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice.
    Balducci C, Mehdawy B, Mare L, Giuliani A, Lorenzini L, Sivilia S, Giardino L, Calzà L, Lanzillotta A, Sarnico I, Pizzi M, Usiello A, Viscomi AR, Ottonello S, Villetti G, Imbimbo BP, Nisticò G, Forloni G, Nisticò R.
    J Alzheimers Dis; 2011 Mar 05; 24(4):799-816. PubMed ID: 21321397
    [Abstract] [Full Text] [Related]

  • 8. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice.
    Beggiato S, Giuliani A, Sivilia S, Lorenzini L, Antonelli T, Imbimbo BP, Giardino L, Calzà L, Ferraro L.
    Neuroscience; 2014 Apr 25; 266():13-22. PubMed ID: 24530449
    [Abstract] [Full Text] [Related]

  • 9. CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice.
    Giuliani A, Beggiato S, Baldassarro VA, Mangano C, Giardino L, Imbimbo BP, Antonelli T, Calzà L, Ferraro L.
    J Neurochem; 2013 Mar 25; 124(5):613-20. PubMed ID: 23278303
    [Abstract] [Full Text] [Related]

  • 10. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology.
    Apelt J, Schliebs R.
    Brain Res; 2001 Mar 09; 894(1):21-30. PubMed ID: 11245811
    [Abstract] [Full Text] [Related]

  • 11. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.
    Kawahara K, Suenobu M, Ohtsuka H, Kuniyasu A, Sugimoto Y, Nakagomi M, Fukasawa H, Shudo K, Nakayama H.
    J Alzheimers Dis; 2014 Mar 09; 42(2):587-605. PubMed ID: 24916544
    [Abstract] [Full Text] [Related]

  • 12. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.
    Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM.
    BMC Neurosci; 2007 Jul 24; 8():54. PubMed ID: 17650315
    [Abstract] [Full Text] [Related]

  • 13. Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation.
    Porrini V, Sarnico I, Benarese M, Branca C, Mota M, Lanzillotta A, Bellucci A, Parrella E, Faggi L, Spano P, Imbimbo BP, Pizzi M.
    Int J Mol Sci; 2017 Jan 18; 18(1):. PubMed ID: 28106772
    [Abstract] [Full Text] [Related]

  • 14. The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.
    Lanzillotta A, Sarnico I, Benarese M, Branca C, Baiguera C, Hutter-Paier B, Windisch M, Spano P, Imbimbo BP, Pizzi M.
    J Mol Neurosci; 2011 Sep 18; 45(1):22-31. PubMed ID: 21181298
    [Abstract] [Full Text] [Related]

  • 15. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology.
    van Groen T, Miettinen P, Kadish I.
    J Alzheimers Dis; 2011 Sep 18; 24(2):301-13. PubMed ID: 21239852
    [Abstract] [Full Text] [Related]

  • 16. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology.
    van Groen T, Kadish I.
    Brain Res Brain Res Rev; 2005 Apr 18; 48(2):370-8. PubMed ID: 15850676
    [Abstract] [Full Text] [Related]

  • 17. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
    Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN.
    J Neurosci; 2002 Mar 15; 22(6):2246-54. PubMed ID: 11896164
    [Abstract] [Full Text] [Related]

  • 18. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
    Maezawa I, Nguyen HM, Di Lucente J, Jenkins DP, Singh V, Hilt S, Kim K, Rangaraju S, Levey AI, Wulff H, Jin LW.
    Brain; 2018 Feb 01; 141(2):596-612. PubMed ID: 29272333
    [Abstract] [Full Text] [Related]

  • 19. Quetiapine attenuates glial activation and proinflammatory cytokines in APP/PS1 transgenic mice via inhibition of nuclear factor-κB pathway.
    Zhu S, Shi R, Li V, Wang J, Zhang R, Tempier A, He J, Kong J, Wang JF, Li XM.
    Int J Neuropsychopharmacol; 2014 Oct 31; 18(3):. PubMed ID: 25618401
    [Abstract] [Full Text] [Related]

  • 20. Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease.
    Couturier J, Stancu IC, Schakman O, Pierrot N, Huaux F, Kienlen-Campard P, Dewachter I, Octave JN.
    J Neuroinflammation; 2016 Jan 27; 13():20. PubMed ID: 26818951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.